Navigation Links
Universal flu vaccine clinical trials show promise

GALVESTON, Texas A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

The results of the clinical trials, led by the University of Texas Medical Branch at Galveston in collaboration with biotechnology company VaxInnate and funded by $9.5 million grant from the Bill and Melinda Gates Foundation, were published today online in the journal Vaccine.

The vaccine candidate, VAX102, targets a protein known as M2e, found on the surface of the influenza A virus, that has remained relatively unchanged over the last century. VAX102 consists of 4 copies of M2e fused to the protein flagellin, a TLR5 ligand used as an adjuvant. The M2e antigen had been completely unchanged from 1918 until the recent pandemic, making it of interest to researchers searching for a target for the immune response to influenza that would be stable over many seasons.

Unlike traditional flu vaccines, which target antigens that change continuously, the prototype VAX102 represents a vaccine that would not require annual updates, an important barrier to influenza prevention throughout the world. The technology used to produce the candidate vaccine would eliminate many of the limitations of current influenza vaccines, including inefficiencies related to manufacturing such as limited production capability and the inability to change the target antigen should the vaccine not match the circulating strains.

"As we saw in the 2009 influenza pandemic, there is a great public and global health need for a rapid, scalable model for vaccine production," said lead author Christine B. Turley, M.D., Vice Chair for Clinical Services, Department of Pediatrics and a member of UTMB's Sealy Center for Vaccine Development. "If ultimately proven effective, VAX102 will meet this need and offer a completely new approach to global flu prevention and control."

Two studies, conducted at UTMB and Johnson County Clin-Trials in Lenexa, Kansas, assessed the safety, tolerability and immunogenicity the induced immune response of VAX102.

Healthy adults ages 18-49 were randomly assigned to receive two doses of either vaccine or placebo. The two studies established the dose range for further study. Doses ranging from 0.03 to 10 micrograms were studied. Individuals at the highest doses had more systemic reactions; doses of 1 microgram or less were safe. All vaccinated subjects showed some degree of antibody response, with a more than four-fold increase noted in all groups by 14 days after the second dose of vaccine.

An important next step will be studies to determine the degree to which the vaccine may be effective against influenza infection. Future studies would also investigate the durability of the antibody response and more closely assess cytokine responses proteins released as part of the immune response in an effort to better understand, predict and potentially prevent the adverse reactions noted at highest doses.

Pending results of future trials, VAX102 could be used as a stand-alone vaccine to prevent influenza A infection. Other possible strategies include use in conjunction with vaccines that target traditional influenza antigens, as a part of an approach to increase efficacy when infection occurs with mismatched strains.

VAX102 efficacy would have major global health implications, as worldwide annual influenza vaccination is not currently available due to limitations of licensed vaccines and international immunization infrastructure.

According to Turley, an influenza vaccine that can be produced rapidly and with great economies of scale, such as VAX102 through simple bacterial fermentation, allows for an entirely new approach to international influenza control. Further, because the M2e-based vaccine would not require annual updates, it could be useful to offer protection over multiple influenza seasons.

Finally, VAX102 holds promise as an improved vaccine for the elderly. "Our immune response deteriorates with age," said Turley. "Currently, the elderly aren't afforded as much protection from the flu vaccine as younger individuals. Rather than giving the elderly higher doses of a vaccine each year, VAX102 could afford long-term protection or be used as a booster strategy, maximizing immune memory."


Contact: Jim Kelly
University of Texas Medical Branch at Galveston

Related medicine news :

1. Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results
2. Families Fighting Flu Commends the CDCs Advisory Committee on Immunization Practices Recommendation for Universal Influenza Vaccination
3. New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid
4. Universal Health Care Debate Coincides with Release of My eMHR, the Nation's First Free Electronic Personal Health Records System
5. Mount Sinai researchers move closer to a universal influenza vaccine
6. Mount Sinai researchers approaching universal treatment for all strains of influenza
7. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
8. Study shows universal surveillance for MRSA significantly decreased HAIs at PCMH
9. AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access
10. Government urges universal flu vaccinations
11. Experts recommend universal screening of newborns for congenital adrenal hyperplasia
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased ... moderate facial wrinkling. While many patients are aware of the benefits of Botox® in ... delivers to those suffering with discomfort, soreness, and pain as a result of Jaw ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... 2015  Array BioPharma Inc. (Nasdaq: ARRY ... Ron Squarer , will present at the ... The public is welcome to participate in the ... website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, ... p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
Breaking Medicine Technology: